-+ 0.00%
-+ 0.00%
-+ 0.00%

Rezolute reports FDA meeting outcomes for its Phase 3 sunRIZE trial of ersodetug in congenital hyperinsulinism

Reuters·03/24/2026 11:02:35

Please log in to view news